Time course and recovery of arterial blood gases during exacerbations in adults with Cystic Fibrosis.
AffiliationDepartment of Respiratory Medicine, St. Vincent's University Hospital, Ireland.
Anti-Bacterial Agents/therapeutic use
*Blood Gas Analysis
Bronchodilator Agents/therapeutic use
Cystic Fibrosis/*blood/*complications/drug therapy
Drug Therapy, Combination
Recovery of Function
MetadataShow full item record
CitationJ Cyst Fibros. 2009 Jan;8(1):9-13. Epub 2008 Aug 20.
JournalJournal of cystic fibrosis : official journal of the European Cystic Fibrosis, Society
AbstractINTRODUCTION: Hypoxia and hypercapnia are closely linked to morbidity and mortality in patients with Cystic Fibrosis (CF). The aims of this study were to describe the changes in blood gases during and following an acute pulmonary exacerbation in adults with CF. METHODS: We performed a prospective observational study of patients with CF admitted for management of an acute exacerbation. Blood gas and spirometric analysis was performed on admission, throughout the treatment period, and 31 days after discharge (day 45). RESULTS: At presentation, eight of nineteen patients had evidence of either hypoxia (PaO(2)<8 kPa) and/or hypercapnia (PaCO(2)>6.6 kPa). Blood gas parameters stabilized following two weeks of intravenous antibiotic therapy, with little difference evident in between treatment completion and subsequent review following discharge. Hypercapnia reversed in three patients, with persistent hypercapnia evident in two patients. CONCLUSION: In our study group, hypoxemia and hypercapnia were frequently observed at presentation of the acute exacerbation. Blood gases stabilized following two weeks of intravenous antibiotic therapy, with arterial PCO(2) one month following hospital discharge generally similar to that at time of discharge.
- Metabolic alkalosis contributes to acute hypercapnic respiratory failure in adult cystic fibrosis.
- Authors: Holland AE, Wilson JW, Kotsimbos TC, Naughton MT
- Issue date: 2003 Aug
- Explained variance for blood gases in a population with COPD.
- Authors: Saure EW, Eagan TM, Jensen RL, Voll-Aanerud M, Aukrust P, Bakke PS, Hardie JA
- Issue date: 2012 Apr
- Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.
- Authors: VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW
- Issue date: 2010 Oct 6
- Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
- Authors: Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Goss CH
- Issue date: 2013 Nov
- Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
- Authors: Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F
- Issue date: 2015 Nov